Drug Search Results
More Filters [+]

PB-1023

Alternative Names: pb-1023, pb1023, pb 1023
Latest Update: 2020-09-15
Latest Update Note: News Article

Product Description

a long-acting, recombinant GLP-1 analogue for the treatment of certain diseases, including conditions related to sarcopenia. PB1023 was created as a genetic fusion protein utilizing PhaseBioÕs proprietary elastin-like polypeptide (ÒELPÓ) technology platform. (Sourced from: https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-global-license-pb1023-treatment-sarcopenia)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PhaseBio
Company Location: MALVERN PA 19355
Company CEO: Jonathan P. Mow
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PB-1023

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: Type 2 Diabetes|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PB1023-PT-CL-0004

P2

Completed

Type 2 Diabetes

2013-07-01

PB1023-PT-CL-0003

P1

Completed

Type 2 Diabetes|Kidney Diseases

2012-10-01

PB1023-PT-CL-0002

P1

Completed

Type 2 Diabetes

2012-09-01

PB1023-PT-CL-0001

P2

Completed

Type 2 Diabetes

2011-11-01

Recent News Events